• Publications
  • Influence
Economic burden of resected squamous cell carcinoma of the head and neck in a US managed-care population
Abstract Background: Squamous cell carcinoma of the head and neck (SCCHN) places a high burden on society and poses complex challenges to healthcare providers. Methods: Retrospective claims-basedExpand
  • 17
  • 1
Comparative analysis of survival, treatment, cost and resource use among patients newly diagnosed with brain metastasis by initial primary cancer
Brain metastases are a frequent complication of many systemic cancers and portend a poor prognosis. This retrospective analysis of health claims data compared survival, treatment and health careExpand
  • 20
  • 1
Corroboration of claims algorithm for second-line costs of metastatic colorectal cancer treatment with targeted agents
Abstract Objective: To refine a claims algorithm for identifying second-line systemic regimens for metastatic colorectal cancer (mCRC) based on clinical evidence and to compare costs duringExpand
  • 6
  • 1
Health care utilization and costs by site of service for nonmetastatic breast cancer patients treated with trastuzumab.
BACKGROUND Adjuvant trastuzumab treatment is administered to early stage breast cancer patients in physician office (POV) or hospital outpatient (HOP) settings. OBJECTIVE To identify treatmentExpand
  • 7
  • 1
  • PDF
Clinical and economic outcomes by first-line treatment among women with HR+/HER2– metastatic breast cancer in a large US health plan database
Abstract Background: Guidelines recommend that women with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) metastatic breast cancer (mBC) initiate hormonalExpand
  • 6
  • 1
Persistency with zoledronic acid is associated with clinical benefit in patients with multiple myeloma
Zoledronic acid (ZOL), an intravenous bisphosphonate, has been shown to reduce and delay the incidence of skeletal‐related events (SREs) in multiple myeloma (MM) patients with bone disease. AExpand
  • 17
Patient survival and healthcare utilization costs after diagnosis of triple-negative breast cancer in a United States managed care cancer registry
Abstract Background: Triple-negative breast cancer (TNBC) makes up 10–17% of all breast cancers and, due to lack of receptor expression, is unresponsive to therapies that target hormonal receptors orExpand
  • 16
Healthcare costs, treatment patterns, and resource utilization among pancreatic cancer patients in a managed care population
Abstract Background: Pancreatic adenocarcinoma has few effective treatment options and poor survival. The objective of this study was to characterize treatment patterns and estimate the costs andExpand
  • 12
Evaluation of the clinical benefit of long-term (beyond 2 years) treatment of skeletal-related events in advanced cancers with zoledronic acid
Abstract Background: Skeletal complications of malignant bone disease are common among patients with both solid tumors and multiple myeloma (MM). Zoledronic acid (ZOL; Zometa) is an intravenousExpand
  • 14